ABBY DAVIS: Open Payments
NPI 1457873044 · PASADENA, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,239 in 34 payments from 8 companies in 2025. Trend: 2023 $321 · 2024 $521 · 2025 $1,239
Food & beverage: $1,180Education: $59
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $346 |
| ARS Pharmaceuticals Operations, Inc. | 7 | $317 |
| Genentech USA, Inc. | 4 | $194 |
| GlaxoSmithKline, LLC. | 7 | $156 |
| GENZYME CORPORATION | 3 | $101 |
| Regeneron Healthcare Solutions, Inc. | 2 | $79 |
| PFIZER INC. | 2 | $32 |
| Greer Laboratories, Inc. | 1 | $15 |
Products named: NEFFY, AIRSUPRA, Xolair, NUCALA, DUPIXENT, TRELEGY ELLIPTA, FASENRA, NURTEC ODT.
Industry payments across MD — which companies pay providers there.
